Adrenaline (base) 5mg/5ml (1 in 1,000) solution for injection ampoules 영국 - 영어 - MHRA (Medicines & Healthcare Products Regulatory Agency)

adrenaline (base) 5mg/5ml (1 in 1,000) solution for injection ampoules

base) 5mg/5ml (1 in 1,000) solution for injection ampoules (martindale pharmaceuticals ltd - adrenaline acid tartrate - solution for injection - 1mg/1ml

Adrenaline (base) 100micrograms/1ml (1 in 10,000) dilute solution for injection pre-filled syringes 영국 - 영어 - MHRA (Medicines & Healthcare Products Regulatory Agency)

adrenaline (base) 100micrograms/1ml (1 in 10,000) dilute solution for injection pre-filled syringes

base) 100micrograms/1ml (1 in 10,000) dilute solution for injection pre-filled syringes (martindale pharmaceuticals ltd - adrenaline acid tartrate - solution for injection - 100microgram/1ml

Adrenaline (base) 1mg/10ml (1 in 10,000) dilute solution for injection ampoules 영국 - 영어 - MHRA (Medicines & Healthcare Products Regulatory Agency)

adrenaline (base) 1mg/10ml (1 in 10,000) dilute solution for injection ampoules

base) 1mg/10ml (1 in 10,000) dilute solution for injection ampoules (martindale pharmaceuticals ltd - adrenaline acid tartrate - solution for injection - 100microgram/1ml

Adrenaline (base) 1mg/1ml (1 in 1,000) solution for injection ampoules 영국 - 영어 - MHRA (Medicines & Healthcare Products Regulatory Agency)

adrenaline (base) 1mg/1ml (1 in 1,000) solution for injection ampoules

base) 1mg/1ml (1 in 1,000) solution for injection ampoules (hameln pharma ltd - adrenaline acid tartrate - solution for injection - 1mg/1ml

Adrenaline (base) 1mg/1ml (1 in 1,000) solution for injection ampoules 영국 - 영어 - MHRA (Medicines & Healthcare Products Regulatory Agency)

adrenaline (base) 1mg/1ml (1 in 1,000) solution for injection ampoules

base) 1mg/1ml (1 in 1,000) solution for injection ampoules (advanz pharma - adrenaline acid tartrate - solution for injection - 1mg/1ml

Adrenaline (base) 1mg/10ml (1 in 10,000) dilute solution for injection pre-filled syringes 영국 - 영어 - MHRA (Medicines & Healthcare Products Regulatory Agency)

adrenaline (base) 1mg/10ml (1 in 10,000) dilute solution for injection pre-filled syringes

base) 1mg/10ml (1 in 10,000) dilute solution for injection pre-filled syringes (martindale pharmaceuticals ltd - adrenaline - solution for injection - 100microgram/1ml

Adrenaline (base) for anaphylaxis 1mg/1ml (1 in 1,000) solution for injection pre-filled syringes 영국 - 영어 - MHRA (Medicines & Healthcare Products Regulatory Agency)

adrenaline (base) for anaphylaxis 1mg/1ml (1 in 1,000) solution for injection pre-filled syringes

base) for anaphylaxis 1mg/1ml (1 in 1,000) solution for injection pre-filled syringes (martindale pharmaceuticals ltd - adrenaline - solution for injection - 1mg/1ml

Adrenaline (base) 10mg/10ml (1 in 1,000) solution for injection ampoules 영국 - 영어 - MHRA (Medicines & Healthcare Products Regulatory Agency)

adrenaline (base) 10mg/10ml (1 in 1,000) solution for injection ampoules

base) 10mg/10ml (1 in 1,000) solution for injection ampoules (martindale pharmaceuticals ltd - adrenaline - solution for injection - 1mg/1ml

Adrenaline (base) 1mg/10ml (1 in 10,000) dilute solution for injection pre-filled syringes 영국 - 영어 - MHRA (Medicines & Healthcare Products Regulatory Agency)

adrenaline (base) 1mg/10ml (1 in 10,000) dilute solution for injection pre-filled syringes

base) 1mg/10ml (1 in 10,000) dilute solution for injection pre-filled syringes (aguettant ltd - adrenaline - solution for injection - 100microgram/1ml

Calcium Folinate Sandoz 뉴질랜드 - 영어 - Medsafe (Medicines Safety Authority)

calcium folinate sandoz

sandoz new zealand limited - calcium folinate pentahydrate 10.8 mg/ml (as 12.71 mg/ml of calcium folinate pentahydrate, equivalent to 10 mg/ml folinic acid) - concentrate for injection - 100 mg/10ml - active: calcium folinate pentahydrate 10.8 mg/ml (as 12.71 mg/ml of calcium folinate pentahydrate, equivalent to 10 mg/ml folinic acid) excipient: hydrochloric acid nitrogen sodium chloride sodium hydroxide water for injection - as rescue therapy to reduce toxicity following high-dose methotrexate therapy. has shown good results in the treatment of certain megaloblastic anaemias resulting from folic acid deficiency. this mainly occurs in infants, during pregnancy, in malabsorption syndromes, liver diseases, sprue and malnutrition. it is not more effective than folic acid for these conditions overdosage of methotrexate and in impaired methotrexate elimination reducing the toxicity and circumventing the effect of folic acid antagonists